SHARE ON: |
| |
| |
 |
 |
|
|
COVID-19 antibody tests that deliver a result on the spot are unreliable enough that they should stop being used immediately, according to new Canadian-led research.
The research, which was published Wednesday in The BMJ, involved a review of all known studies about the effectiveness of the antibody tests.
Finding dependable information was not easy. The researchers ended up with 40 studies to look over, 70 per cent of which came from China. Most of the studies were found to have been designed in a way that could create a bias in the results, and about half had not been peer-reviewed.
Still, the researchers say the studies were enough for them to reach one clear conclusion: there are major weaknesses in the existing evidence supporting the use of blood tests that do not process their samples in laboratory settings.
The evidence does not support the continued use of existing point-of-care serological tests for COVID-19, they wrote.
Serological tests are used to determine whether a person has developed antibodies against COVID-19, which would suggest that they have already fought off the disease once and are theoretically immune to a second infection.
They can also be used to diagnose active cases of COVID-19, although the medical standard for that is to use molecular tests, which require lab processing, making them more expensive and with longer wait times before results are provided.
The increasing rollout of the serological tests has led to the idea of immunity passports, where antibody test results could be used by governments to track which citizens have and have not developed the antibodies.
Although this idea might sound promising – allowing those who have already had COVID-19 to live their lives with limited restrictions while those who have not can remain in isolation – health authorities including the World Health Organization and Canadas chief public health officer have been more negative, arguing that immunity passports should not be considered until there is more evidence of how long the antibodies last.
There are other objections as well, ranging from privacy concerns to potential discrimination to the possibility that some people may intentionally infect themselves in order to develop immunity.
The new research pours even more cold water on the idea, finding that the serological tests have relatively high error rates. These errors can take the form of false positives, where the disease is said to be found in someone who does not have it, or false negatives, where an infected persons antibodies do not show up in the results.
The researchers found that the studied serological tests fared relatively well when it came to avoiding false positives, with this happening between 0.3 per cent and 3.4 per cent of the time.
False negatives were a much bigger problem, with some tests failing to detect COVID-19 antibodies in up to 34 per cent of all those tested who had been infected.
The tests that presented the most false negatives were those of the lateral flow immunoassay (LFIA) variety – the type being considered for use in immunity passports because its lack of a need for lab processing makes it quicker and cheaper than the alternatives.
In the U.S., the Centers for Disease Control and Prevention have warned that antibody tests can deliver false results up to 50 per cent of the time.
According to the researchers, their findings suggest that if LFIA tests are given to 100 people who have had COVID-19 and 900 who have not, 34 of those with the antibodies will be wrongly told they do not have them, and 31 of those without will be wrongly told they do.
Overall, the poor performance of existing serological tests for COVID-19 raises questions about the utility of using such methods for medical decision making, they wrote.
While the scientific community should be lauded for the pace at which novel serological tests have been developed, this review underscores the need for high quality clinical studies to evaluate these tools.
The research team was led by McGill University in Montreal and also included contributions from the University of Sherbrooke, the University of British Columbia, the State University of Rio de Janeiro and Harvard Medical School.
|
 |
|
 |
|
 |
|
 |
3 am |
| -8 ℃ |
| OVERCAST CLOUDS |
WIND: NE 8 KM/H
GUSTING TO 11 KM/H |
|
|
|
4 am |
| -8 ℃ |
| OVERCAST CLOUDS |
WIND: NE 9 KM/H
GUSTING TO 13 KM/H |
|
|
|
5 am |
| -8 ℃ |
| OVERCAST CLOUDS |
WIND: NNE 8 KM/H
GUSTING TO 8 KM/H |
|
|
|
6 am |
| -8 ℃ |
| OVERCAST CLOUDS |
WIND: NNE 11 KM/H
GUSTING TO 18 KM/H |
|
|
|
7 am |
| -9 ℃ |
| BROKEN CLOUDS |
WIND: NNE 10 KM/H
GUSTING TO 19 KM/H |
|
|
|
8 am |
| -11 ℃ |
| BROKEN CLOUDS |
WIND: NNW 11 KM/H
GUSTING TO 15 KM/H |
|
|
 |
9 am |
| -14 ℃ |
| OVERCAST CLOUDS |
WIND: N 12 KM/H
GUSTING TO 21 KM/H |
|
|
|
10 am |
| -16 ℃ |
| OVERCAST CLOUDS |
WIND: N 12 KM/H
GUSTING TO 23 KM/H |
|
|
|
 |
TODAY |
HIGH OF -7 ℃
LOW OF -17 ℃ |
| LIGHT SNOW |
|
|
|
SUNDAY |
HIGH OF -17 ℃
LOW OF -27 ℃ |
| OVERCAST CLOUDS |
|
|
|
MONDAY |
HIGH OF -6 ℃
LOW OF -26 ℃ |
| OVERCAST CLOUDS |
|
|
|
TUESDAY |
HIGH OF -1 ℃
LOW OF -16 ℃ |
| LIGHT SNOW |
|
|
|
WEDNESDAY |
HIGH OF -16 ℃
LOW OF -27 ℃ |
| LIGHT SNOW |
|
|
 |
THURSDAY |
HIGH OF -22 ℃
LOW OF -29 ℃ |
| FEW CLOUDS |
|
|
|
FRIDAY |
HIGH OF -8 ℃
LOW OF -22 ℃ |
| OVERCAST CLOUDS |
|
|
|
SATURDAY |
HIGH OF 3 ℃
LOW OF -11 ℃ |
| BROKEN CLOUDS |
|
|
|
|
|
 |
 |
|
| Canadian Tire New Year Sale – Start 2026 Saving! |
| |
| Ring in 2026 with Canadian Tire! Save on home, garage, and outdoor essentials to kick off the year right. |
| |
| New Year deals won’t last—shop Canadian Tire today! |
|
 |
|
 |
|
|
 |
 |
DOMINUM
THE DEAD DONT DIE
03:19 AM |
|
 |
ESCAPE THE FATE
ALIVE
03:13 AM |
|
 |
THE SCORE
VISIONS
03:09 AM |
|
 |
SKILLET
SURVIVING THE GAME
03:05 AM |
|
 |
BUCKCHERRY
SHINE YOUR LIGHT
03:01 AM |
|
 |
ACDC
GIVE IT UP
02:57 AM |
|
 |
DUSTY GRANT
SINKING FURTHER
02:54 AM |
|
 |
COREY TAYLOR
TALK SICK
02:50 AM |
|
 |
SILENT THEORY
MADE ME THIS WAY
02:43 AM |
|
 |
AD INFINITUM
SURRENDER
02:39 AM |
|
 
 |
